# Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer

> **NCT00182767** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 45 (actual)

## Conditions studied

- Fallopian Tube Cancer
- Female Reproductive Cancer
- Recurrent Breast Cancer
- Recurrent Ovarian Epithelial Cancer
- Stage III Ovarian Epithelial Cancer
- Stage IV Breast Cancer
- Stage IV Ovarian Epithelial Cancer

## Interventions

- **DRUG:** ixabepilone
- **DRUG:** pegylated liposomal doxorubicin hydrochloride

## Key facts

- **NCT ID:** NCT00182767
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2012-04
- **Final completion:** 2014-05
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2016-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00182767

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00182767, "Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00182767. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*